Nurix Therapeutics, Inc. (NRIX) vs Supernus Pharmaceuticals, Inc. (SUPN)
A side-by-side comparison of Nurix Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NRIX
Nurix Therapeutics, Inc.
$22.43HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
SUPN
Supernus Pharmaceuticals, Inc.
$42.53HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — NRIX vs SUPN
growth of $100 · dividends reinvested · last 6yNRIX +20.4% (+3.1%/yr)SUPN +78.8% (+10.2%/yr)SUPN compounded faster over this window
NRIX SUPN
NRIX vs SUPN: by the numbers
- •SUPN is the larger company ($2.47B vs $2.33B market cap).
- •Both run net losses; SUPN's is the smaller (-13.23% vs -928.44% net margin).
- •NRIX grew revenue faster over the past five years (9.96% vs 7.78% CAGR).
Metrics side by side
Valuation
| Metric | NRIX | SUPN |
|---|---|---|
| Forward P/E | N/A | 16.58 |
| P/S ratio | 63.31 | 2.97 |
| P/B ratio | 5.78 | 2.39 |
| FCF yield | N/A | 0.76% |
Profitability
| Metric | NRIX | SUPN |
|---|---|---|
| Gross margin | 77.55% | 88.07% |
| Operating margin | -340.16% | -5.13% |
| Net margin | -928.44% | -13.23% |
| ROE | -84.78% | -10.66% |
| ROIC | -77.92% | -10.24% |
Growth (annualized)
| Metric | NRIX | SUPN |
|---|---|---|
| Revenue CAGR (5Y) | 9.96% | 7.78% |
| FCF CAGR (5Y) | N/A | -30.77% |
| Total return CAGR (5Y) | -5.51% | 9.85% |
Frequently asked
- Which has grown faster, NRIX or SUPN?
- Over the past five years, NRIX grew revenue faster — NRIX at a 9.96% CAGR versus SUPN at 7.78%.
- How have NRIX and SUPN total returns compared?
- Over the past 5 years, NRIX delivered -5.51% and SUPN delivered 9.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.